

Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with HER2-Positive Breast Cancer — Part 1 of a 5-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What did the interim results from the Phase III DESTINY-Breast03 study demonstrate regarding progression-free survival with trastuzumab deruxtecan compared to T-DM1 for patients with HER2-positive, unresectable and/or metastatic breast cancer after previous treatment with trastuzumab and a taxane?

 - a. Improvement with T-DM1
 - b. Improvement with trastuzumab deruxtecan
 - c. Similar progression-free survival in both study arms
2. What did results from the Phase III KATHERINE study demonstrate regarding invasive disease-free survival with T-DM1 compared to trastuzumab as adjuvant therapy for patients with early-stage HER2-positive breast cancer and residual disease after neoadjuvant chemotherapy/trastuzumab?

 - a. Improvement with T-DM1
 - b. Improvement with trastuzumab
 - c. Similar invasive disease-free survival in both study arms
3. Which of the following conditions was reported as an adverse event of special interest in the DESTINY-Breast01 trial of trastuzumab deruxtecan for previously treated metastatic HER2-positive breast cancer?

 - a. New secondary cancer
 - b. Ocular toxicities
 - c. Interstitial lung disease
4. Which of the following drug types best describes the novel agent trastuzumab deruxtecan?

 - a. Tyrosine kinase inhibitor
 - b. Antibody-drug conjugate
 - c. Immune checkpoint inhibitor